|
|
|
|
|
Somatic Mutation Detection
|
| BRAF mutation (V600E) Detection |
Seeplex® BRAF V600E ACE Detection is
designed to detect
BRAF mutation (V600E)
characteristic for papillary thyroid carcinoma.
(Analyzing product, DNA amplification )
|
|
|
   |
|
|
|
 |
Seeplex® BRAF V600E ACE Detection is designed to detect BRAF mutation (V600E) from thyroid tissue or fine needle aspiration cytology. The BRAF gene involves in mediating cellular response to growth, differentiation and death signals in RAS RAF MEK MAP kinase pathway. BRAF mutations are common in melanoma, colon cancer, gliomas, and lung cancer. In 80% cases, it is a single substitution1),2) (V600E). Especially, in papillary thyroid carcinoma (PTC), the incidence of BRAF mutation occurs 26-69% (likely 45-50%) of all cases1),3).
Seeplex® BRAF V600E ACE Detection tests BRAF mutation, the most common genetic mutation in PTC, with single PCR reaction by utilizing DPO™ technology.
1. M Xing Endocrine-Related Cancer (2005) 12 245–262
2. HIROYUKI NAMBA et al. J Clin Endocrinol Metab 88:4393–4397, 2003
3. L Fugazzola et al. Endocrine-Related Cancer (2006) 13 455-464 |
 |
| A. |
Detection of V600E mutation of the BRAF gene in papillary thyroid carcinoma |
| B. |
Multiplex PCR with high sensitivity and specificity by applying DPO™ (Dual Priming Oligonucleotide) technology |
| C. |
Detect up to 2% of mutation |
| D. |
Test within 5 hours |
| E. |
Provide viewer software for convenient result analysis |
| |
|
|
 |
- Thyroid fresh tissue
- Fine needle aspiration biopsy
- Thyroid H&E slide
- Paraffin-embedded tissue
- Liquid based cytology specimen
(e.g., ThinPrep® and SurePath™) |
|
 |
| - V600E |
|
 |
 |
ScreenTape® System
(Agilent Technologies)
 |
 |
MCE®-202
MultiNA
SHIMADZU
|
|
|
|
 |
| Product |
Cat. No. |
Size |
| Seeplex® BRAF V600E ACE Detection |
BR6100Z |
25 rxns |
|
|
|
|
- As this product is Medical Device, please read 'caution' and 'instruction' before use.
- Deliberation number : 2013-I10-01-0834
|
|
|
|
|
|
